DELRAY BEACH, Fla., May 9, 2025 /PRNewswire/ — The global Artificial Intelligence (AI) in Healthcare Market, valued at US$14.92 billion in 2024, is forecasted to grow at a robust CAGR of 38.6%, reaching US$21.66 billion in 2025 and an impressive US$110.61billion by 2030. The growing incidence of chronic diseases, linked with an increasing geriatric population, puts substantial financial pressure on healthcare providers. There is a rising need for the early detection of conditions such as dementia and cardiovascular disorders. This can be done by analysing imaging data to recognize patterns, which helps create personalized treatment plans. 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54679303

Browse in-depth TOC on “Artificial Intelligence (AI) in Healthcare Market”

882 – Tables
61 – Figures
738 – Pages

By tools, the Artificial Intelligence (AI) in healthcare market for machine learning has been bifurcated into deep learning, supervised learning, reinforcement learning, unsupervised learning, and other machine learning technologies. The deep learning segment accounted for the largest share of the Artificial Intelligence (AI) in healthcare market in 2024. The capability to process vast amounts of unstructured medical data, such as electronic health records (HER), imaging, and genomics, allows accurate disease diagnosis and prediction. The integration of deep learning into healthcare is significantly boosting the AI in healthcare market, leading to substantial investments in diagnostic tools and predictive analytics. As computational power and data availability continue to increase, deep learning is set to unlock further advancements, solidifying its position as a key enabler of next-generation healthcare technologies.

By end user, the AI in healthcare market is segmented into healthcare providers, healthcare payers, patients, and other end users. In 2024, healthcare providers accounted for the largest share of the AI in healthcare market. The large share of this end-user segment can be attributed to the increasing budgets of hospitals to improve the quality of care provided and reduce the cost of care.

By geography, the Artificial Intelligence (AI) in healthcare market is segmented into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to see a substantial growth rate during the forecast period. The Asia Pacific (APAC) region is experiencing substantial growth in adopting AI technologies within the healthcare sector, driven by a combination of demographic shifts, technological advancements, and increased investments in innovation. The rising elderly population in the region is a key factor, with the proportion of individuals aged 65 years and above increasing significantly. The demand for advanced healthcare solutions has surged as the aging population faces chronic and age-related conditions, necessitating efficient diagnostic, monitoring, and treatment tools. AI technologies are being integrated into various healthcare applications, including predictive analytics, telemedicine, medical imaging, and patient management systems. These innovations aim to address gaps in healthcare access, improve diagnostic accuracy, and streamline operations across the region.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=54679303

The prominent players operating in the Artificial Intelligence (AI) in healthcare market include Koninklijke Philips N.V. (Netherlands), Microsoft Corporation  (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US), GE Healthcare (US), Medtronic (US), Oracle (US), Veradigm LLC  (US), Merative (IBM) (US), Google (US), Cognizant (US), Johnson & Johnson (US), Amazon Web Services, Inc. (US), among others. These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers, and acquisitions to strengthen their market presence in the Artificial Intelligence (AI) in healthcare market.

Koninklijke Philips N.V. (Netherlands)

Koninklijke Philips N.V. is a leading player in the AI in the healthcare market. The company utilizes AI to deliver innovative tools across various areas, including diagnostic imaging, patient monitoring, and precision medicine. Its advanced AI-driven platforms, such as the Philips HealthSuite, facilitate the integration and analysis of extensive clinical data, which supports personalized treatment plans and improves patient outcomes. Philips focuses on organic and inorganic growth strategies to expand its market presence.

Strategic partnerships in high-potential markets and collaborations have been the key growth strategies of the company over the years. For example, in February 2025, Philips partnered with Medtronic to educate and train cardiologists and radiologists in India on advanced imaging techniques for structural heart diseases. This partnership aims to upskill 300+ clinicians in multi-modality imaging such as echocardiography (echo) and Magnetic Resonance Imaging (MRI), especially for End-Stage Renal Disease (ESRD) patients. In November 2023, Philips and NYU Langone Health partnered to focus on patient safety and outcomes. This partnership integrated innovative health technologies, including digital pathology, clinical informatics, and AI-enabled diagnostics, enabling real-time collaboration among clinicians. The company also focuses on winning contracts across several companies in the healthcare space. This helps the company expand its footprint. For instance, in September 2022, Philips and Mandaya Royal Hospital Puri (MRHP) in Jakarta underwent a digital transformation in a strategic partnership, enhancing patient-centered care and healthcare services.

Microsoft Corporation (US):

Microsoft Corporation is one of the leading providers of software & tools that include advanced AI capabilities in healthcare to improve patient outcomes, streamline operations, and drive innovation. Its Azure-based AI solutions support distinct applications such as medical imaging, genomics, and precision medicine. The company also provides healthcare-specific AI models through its Azure AI Model Catalog, which is constructed to support hospitals and research institutions in building and deploying tailored AI solutions proficiently. Moreover, the integration of Nuance’s AI-powered clinical and diagnostic tools encourages its capacity to support healthcare providers in decision-making and care delivery. The company continuously brings AI capabilities to the platforms in large-scale customer models. For instance, in March 2025, the company launched Microsoft Dragon Copilot, the first unified voice AI assistant in the healthcare industry that enables clinicians to streamline clinical documentation, surface information, and automate tasks.

Microsoft Corporation has invested significantly in R&D, which has improved its product portfolio and position in the AI market. Machine Learning (ML), deep learning, Natural Language Processing (NLP), and speech processing are the key focus areas of the company in the AI in healthcare market. The company continuously invests in a series of services and computational biology projects, including research support tools for next-generation precision healthcare, genomics, immunomics, CRISPR, and cellular and molecular biologics. It has a strong global presence, with key operations supported through its Azure cloud infrastructure across regions like North America, Europe, Asia-Pacific, and the Middle East.

For more information, Inquire Now!

Related Reports:

Healthcare IT Market

Biomarkers Market

Life Science Instrumentation Market

Bioinformatics Market

Healthcare Analytics Market

Get access to the latest updates on Artificial Intelligence (AI) in Healthcare Companies and Artificial Intelligence (AI) in Healthcare Market Size

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:

Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-ai-in-healthcare-market-worth-us110-61-billion-by-2030-with-38-6-cagr–marketsandmarkets-302450931.html

Women can now collect their own sample from the privacy of home, no speculum required, and mail it to a certified lab to be tested on the same test as the doctor’s office, with the same accuracy.

SAN FRANCISCO, May 9, 2025 /PRNewswire/ — Teal Health®, a women’s health company on a mission to eliminate cervical cancer, today announced the Food and Drug Administration’s (FDA) approval of the Teal Wand™, the first and only at-home vaginal sample self-collection device for cervical cancer screening in the United States. Cervical cancer screenings, commonly referred to as the Pap smear, are critical to a woman’s health, but they are inconvenient and uncomfortable for most. Now women have a new way to screen that is as accurate as going to the doctor’s office, comfortable, and done from home. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged 25–65 at average risk. The at-home screening includes both the Teal Wand collection kit and an end-to-end telehealth service providing virtual access to Teal medical providers who prescribe the kit, review the results from the lab, and support women throughout their at-home screening experience.

Cervical cancer is one of the only cancers that is almost entirely preventable with regular screening, yet more than 1 in 4 women in the U.S. are behind. Whether it’s because a woman can’t get time off work, is unable to find an available appointment, or avoids the discomfort of an in-clinic exam, Teal can provide a comfortable and convenient option. The Teal Wand is a preferred alternative, one that has been built with empathy, is driven by science, and designed to make screening easy, so that more women can take control of their health on their own terms.

“As a mom and a woman, I get how easy it is to put your own health last,” said Kara Egan, CEO and Co-Founder of Teal Health. “That’s why this FDA approval means so much; it’s not just about an innovative new product, it’s about finally giving women an option that makes sense for their lives – something that can be done quickly and comfortably at home. Because when we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day.”

With the Teal Wand, women are testing a sample for HPV (human papillomavirus), the virus that causes nearly all cervical cancers, using the same highly accurate HPV test that medical guidelines recommend and providers use in the clinic – cobas® HPV from Roche. The Teal Wand simply provides a different method of sample collection. Cervical cancer screening has evolved from the Pap smear to HPV primary screening. HPV primary screening demonstrates higher sensitivity compared to the Pap test to identify women who may be at risk of cervical cancer. With this FDA approval, women can use the same test as the doctor’s office, with the same accuracy, but collect their own sample from the privacy of their home, the sample is then conveniently shipped to a certified lab for processing.

Teal Health’s FDA approval was supported by their SELF-CERV study, the largest U.S.-based comparative study of its kind. The study confirmed that self-collected samples using the Teal Wand have the same performance as clinician-collected samples, proven to detect cervical precancer 96% of the time, and that the Teal Wand is a much preferred experience. Study participants reflected the racial, ethnic, and socioeconomic diversity of the U.S. population, underscoring Teal Health’s commitment to clinical excellence, equity, and inclusivity in women’s health research. Notably, 86% of participants said they’d be more likely to stay up to date with cervical cancer screening if they could do it at home, and 94% said they would prefer to self-collect at home with the Teal Wand if they knew it was accurate. The clinical performance and preference for the Teal Wand, alongside Teal’s comprehensive telehealth service, highlight the potential of at-home self-collection to expand access to high-quality cervical cancer screening and improve outcomes.

“As a Principal Investigator in the SELF-CERV trial, I saw firsthand how receptive and excited women were to use the Teal Wand. Cervical cancer is largely preventable, yet screening rates in the U.S. continue to lag, and the FDA approval of this at-home Teal Wand self-collection device is a critical step forward. It offers an evidence-based way to expand access without compromising accuracy.” Said Dr. Christine Conageski, Associate Professor, OB-GYN and Director of the Complex Dysplasia Clinic at the University of Colorado, “But access is only part of the solution. Comprehensive screening must go hand in hand with structured, reliable follow-up. That’s why Teal Health’s approach to not only advancing screening technology but also providing education and support to women through every step of their care and follow-up journey is crucial. That’s how we ensure this breakthrough truly closes the gap.”

With FDA approval in hand, Teal Health is moving quickly to get the Teal Wand to as many women as possible. Kits become available in June, starting in California and expanding nationwide as soon as possible thereafter. Teal is working with major insurance providers and plans to have flexible payment options, helping to remove financial concerns and ensuring more women have access to this preferred at-home screening if they want it.

“The FDA prioritized the review of at-home self-collection, recognizing its potential to increase cervical cancer screening adherence, as emphasized in the recent USPSTF (United States Preventive Services Task Force) draft guidelines,” said Trena Depel, Teal Health’s VP of Clinical, Regulatory, and Quality. “After awarding the Teal Wand Breakthrough Device Designation, the FDA stayed committed to a timely review, leading to approval of a technology that delivers meaningful performance, benefits, and choice. This isn’t just a win for Teal—it’s a win for every woman who deserves a rigorously tested and FDA reviewed at-home cervical cancer screening option.”

The approval of the Teal Wand and the shift toward at-home cervical cancer screening signals a new era in healthcare, one designed around women’s comfort, control, and real-life preferences. Join the waitlist at getteal.com to be the first to know when Teal Health expands to your state. Waitlisters get early access to updates and availability.

About Teal Health
Teal Health is a woman-led company on a mission to improve women’s healthcare experiences – starting with the first FDA-approved at-home cervical cancer screening. By creating the option for a woman to screen for cervical cancer from the comfort of home and providing virtual support along the way, and personalized follow-up when needed, Teal can increase access to this life-saving cancer screening. Teal Health is a member of the Cervical Cancer Roundtable, a joint collaboration between the American Cancer Society and the Biden Cancer Moonshot, a coalition of industry leaders with the goal of eliminating cervical cancer as a public health concern in the US. To learn more, visit www.getteal.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-teal-healths-teal-wandthe-first-and-only-at-home-self-collection-device-for-cervical-cancer-screening-introducing-a-comfortable-alternative-to-in-person-screening-302451189.html

SOURCE Teal Health

FORNEBU, Norway, May 9, 2025 /PRNewswire/ —

Issuer: Aker Horizons ASA

ISIN for bond loan: NO0010923220

Original maturity date: 15 August 2025

New maturity date: 23 May 2025

Redemption price: 100.37 % per cent. of the Nominal Amount (plus accrued and unpaid interest on the redeemed amount)

Other information: The issuer has in a letter to Nordic Trustee (the Bond Trustee) notified that the Issuer will exercise the call option to redeem all of the outstanding bonds in accordance with the Bond Terms. The record date will be 21 May 2025.

This information is published in accordance with the requirements of the Continuing Obligations.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/aker-horizons/r/akh01-esg—key-information-relating-to-full-redemption-of-bond-loan,c4148407

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/akh01-esg–key-information-relating-to-full-redemption-of-bond-loan-302451192.html